Skip to main content
BioArctic logo

BioArctic — Investor Relations & Filings

Ticker · BIOA ISIN · SE0010323311 LEI · 549300Y0OI2WVUNHLC33 ST Professional, scientific and technical activities
Open in API
Filings indexed 432 across all filing types
Latest filing 2020-02-06 Interim / Quarterly Rep…
Country SE Sweden
Listing ST BIOA

About BioArctic

https://www.bioarctic.se/en/

BioArctic is a research-intensive biopharmaceutical company focused on developing disease-modifying treatments, biomarkers, and diagnostics for neurodegenerative diseases. The company's core strategy is based on its proprietary antibody technology, which develops unique treatments that target the misfolded and aggregated proteins considered to be the underlying cause of disorders such as Alzheimer's and Parkinson's disease. Through strategic partnerships with global pharmaceutical companies, BioArctic advances its innovative therapies from research through clinical development and commercialization, aiming to address significant unmet medical needs in neurology.

Recent filings

Filing Released Lang Actions
Interim / Quarterly Report 2019
Interim / Quarterly Report Classification · 1% confidence The document is a 'Full Year Report' for BioArctic AB for the period January–December 2019. It contains comprehensive financial statements, key performance indicators, a CEO commentary, and detailed business updates. It is not an announcement of a report (RPA) because it contains the actual financial data and analysis. It is not a 10-K as that is a specific US regulatory filing, whereas this is an international interim/annual financial report. Therefore, it is classified as an Interim/Quarterly Report (IR) as it covers the full fiscal year performance. FY 2019
2020-02-06 English
BioArctic announces research collaboration with Eisai regarding BAN2401
Regulatory Filings Classification · 1% confidence The document is explicitly titled "Press release" and announces a "research collaboration with Eisai regarding BAN2401." It details financial terms (up to EUR 3.25 million) and timelines for the research program. This type of announcement, detailing a specific business event, partnership, or material development that is not a full financial report (like 10-K or IR) or a formal regulatory filing like a Director's Dealing or Major Shareholding notification, typically falls under general corporate news. Since it is a press release announcing a strategic business development (a research collaboration), and there is no specific category for 'Business Development Announcement', the most appropriate classification among the provided options is 'Regulatory Filings' (RNS) as a general announcement category, or potentially 'Capital/Financing Update' (CAP) if the payment was the primary focus, but here the collaboration is the focus. Given the nature of the announcement (a press release about a strategic partnership/research update), and lacking a specific 'Press Release' or 'Business Update' code, RNS serves as the best general regulatory/corporate announcement fallback. However, since it is a press release announcing a strategic business event, and not a mandatory regulatory filing like a 10-K or DIRS, RNS is the fallback. If the document were focused purely on financing, CAP would apply, but here it's about research collaboration terms. I will classify it as RNS as a general corporate announcement.
2019-12-17 English
BioArctic tillkännager utökat forskningssamarbete med Eisai kring BAN2401
Regulatory Filings Classification · 1% confidence The document is titled "Pressmeddelande" (Press Release) and announces an expanded research collaboration between BioArctic and Eisai regarding the drug candidate BAN2401. It details the financial terms (3.25 MEUR) and the timeline (until June 2021). Crucially, the text ends with a statement indicating it is information that BioArctic AB (publ) is obligated to disclose under the EU's Market Abuse Regulation (MAR) and specifies the time of release. This structure is characteristic of a general regulatory announcement or press release concerning corporate activity, rather than a formal financial report (like 10-K or IR) or a specific shareholder communication (like DEF 14A or AGM-R). Since it is a general regulatory announcement that doesn't fit the highly specific categories like M&A (TAR), Capital Change (CAP), or Director Dealing (DIRS), the most appropriate fallback category is Regulatory Filings (RNS). The document length (5786 chars) is substantial enough that it is the primary announcement itself, not just a notice of publication (RPA).
2019-12-17 Swedish
BioArctic’s partner Eisai presents data from the ongoing BAN2401 Phase 2b extension study in early Alzheimer’s disease
Regulatory Filings Classification · 1% confidence The document is a press release from BioArctic AB announcing that its partner, Eisai, presented data from an ongoing clinical study (BAN2401 Phase 2b extension study) at the CTAD conference. It details clinical findings, mentions future study designs (Phase 3 Clarity AD trial), and includes standard boilerplate information about the companies and the drug. This type of announcement, focusing on clinical trial updates and scientific presentations, is typically classified as an Investor Presentation (IP) if it were the presentation itself, or an Earnings Release (ER) if it were summarizing financial results. Since this is a press release detailing scientific/clinical progress and data presentation, and not a formal regulatory filing (like 10-K or IR) or a management discussion (MDA), it most closely aligns with providing information intended for investors regarding ongoing development. However, given the specific definitions, it is not a formal 'Investor Presentation' (IP) document, nor is it an 'Earnings Release' (ER) as it focuses purely on clinical data, not financial performance highlights. It is a general corporate announcement about research progress. In the absence of a specific 'Clinical Trial Update' category, and noting that it is a formal announcement of data presented at a conference, it fits best under the general 'Regulatory Filings' (RNS) category as a non-standard, material corporate disclosure, or potentially as a precursor/related document to an Investor Presentation. Given the content is a press release announcing data presentation, RNS is the most appropriate fallback for material, non-financial, non-management specific corporate news.
2019-12-09 English
BioArctics partner Eisai presenterar data från den pågående förlängningsstudien efter Fas 2b med BAN2401 i tidig Alzheimers sjukdom
Investor Presentation Classification · 1% confidence The document is a press release ("Pressmeddelande") dated December 5, 2019, announcing that BioArctic's partner, Eisai, presented data from an ongoing Phase 2b extension study for the drug BAN2401 at the CTAD conference. It details clinical findings, quotes the CEO, and mentions the upcoming Phase 3 study design presentation. This is a standard corporate announcement regarding clinical trial progress and data presentation, not a full regulatory report (like 10-K or IR), a formal earnings release (ER), or a transcript (CT). Since it is a specific announcement about clinical trial data presentation and progress, it fits best under the general category of Investor Presentation (IP) or potentially Regulatory Filings (RNS) if no better fit exists. Given the focus on presenting clinical data and updates to investors/the public, Investor Presentation (IP) is the most appropriate specific category, although it is structured as a press release. It is not a formal Earnings Release (ER) as it focuses on drug development, not period financial results. It is not an RPA because it is the content itself, not just an announcement that content is available. Therefore, IP is the best fit for detailed clinical/pipeline updates presented to the market.
2019-12-09 Swedish
BioArctic announces results from interim analysis of the Phase 1/2 study of SC0806 in patients with complete spinal cord injury
Legal Proceedings Report Classification · 1% confidence The document is explicitly titled a "Press release" and announces the results of an interim analysis of a Phase 1/2 clinical study (SC0806) for spinal cord injury, concluding that the study did not meet its primary efficacy endpoint and that the company decided to stop patient inclusion and terminate the project. This type of announcement, detailing clinical trial outcomes and subsequent strategic decisions, is typically classified as an Earnings Release (ER) if it's a periodic financial update, or more generally, a Regulatory Filing (RNS) if it's a specific, material, non-financial announcement required by market abuse regulations (as indicated by the final paragraph: "This information is information that BioArctic AB (publ) is obliged to disclose pursuant to the EU Market Abuse Regulation."). Since it is a specific, material announcement about R&D progress and strategic termination, and not a comprehensive financial report (10-K, IR) or a general earnings summary (ER), the most appropriate general regulatory category for material, non-standard disclosures is RNS. However, given the content is a major operational update that significantly impacts future performance, and it is presented as a press release, it often overlaps with ER content, but ER is defined as initial announcement of *financial* results. This is a clinical trial update. Therefore, RNS (Regulatory Filings / miscellaneous) is the best fit as a catch-all for material, non-standard disclosures not covered by other specific codes.
2019-11-18 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.